ZA200402630B - Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions - Google Patents

Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions

Info

Publication number
ZA200402630B
ZA200402630B ZA2004/02630A ZA200402630A ZA200402630B ZA 200402630 B ZA200402630 B ZA 200402630B ZA 2004/02630 A ZA2004/02630 A ZA 2004/02630A ZA 200402630 A ZA200402630 A ZA 200402630A ZA 200402630 B ZA200402630 B ZA 200402630B
Authority
ZA
South Africa
Prior art keywords
cancers
antibodies
diagnosis
receptor
functional
Prior art date
Application number
ZA2004/02630A
Other languages
English (en)
Inventor
Alexander Barden Julian
Gidley-Baird Angus
Original Assignee
Intreat Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR7431A external-priority patent/AUPR743101A0/en
Priority claimed from AUPR7430A external-priority patent/AUPR743001A0/en
Priority claimed from PCT/AU2002/000061 external-priority patent/WO2002057306A1/fr
Application filed by Intreat Pty Ltd filed Critical Intreat Pty Ltd
Publication of ZA200402630B publication Critical patent/ZA200402630B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2004/02630A 2001-09-03 2004-04-02 Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions ZA200402630B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPR7431A AUPR743101A0 (en) 2001-09-03 2001-09-03 A cancer therapeutic
AUPR7430A AUPR743001A0 (en) 2001-09-03 2001-09-03 Diagnosis and treatment of irritable bowel syndrome
PCT/AU2002/000061 WO2002057306A1 (fr) 2001-01-17 2002-01-17 Anticorps du recepteur p2x7 non fonctionnel, diagnostic et traitement de cancers et autres etats pathologiques
PCT/AU2002/001204 WO2003020762A1 (fr) 2001-09-03 2002-09-03 Anticorps au recepteur p2x7 non fonctionnel, diagnostic et traitement de cancers et d'autres conditions

Publications (1)

Publication Number Publication Date
ZA200402630B true ZA200402630B (en) 2005-06-29

Family

ID=41706691

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2004/02630A ZA200402630B (en) 2001-09-03 2004-04-02 Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions

Country Status (9)

Country Link
JP (1) JP4467973B2 (fr)
CN (2) CN101445555B (fr)
AU (1) AU2002322192B2 (fr)
CA (1) CA2459348C (fr)
MY (1) MY142283A (fr)
NZ (2) NZ549019A (fr)
TW (1) TWI329648B (fr)
WO (1) WO2003020762A1 (fr)
ZA (1) ZA200402630B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100497385C (zh) 2001-01-17 2009-06-10 因特里特控股有限公司 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途
JP4746987B2 (ja) * 2002-12-05 2011-08-10 ケーエルエー−テンカー コーポレイション 散乱計測を用いてオーバレイ誤差を検出する装置および方法
EP1615991A4 (fr) 2003-04-03 2007-12-19 Bristol Myers Squibb Co Polynucleotide codant un nouveau variant d'epissage p2x7 humain appele hbmyp2x7v
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
US20100036101A1 (en) * 2006-10-10 2010-02-11 Angus Gidley-Baird Antibodies against non functional p2x7 receptor
AU2007306924A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Hybridomas producing antibodies against non functional P2X7 receptor
AU2013238152B2 (en) * 2007-09-14 2015-09-24 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
WO2009033233A1 (fr) 2007-09-14 2009-03-19 Biosceptre International Limited Nouveaux épitopes p2x7
ATE542139T1 (de) * 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
CN101469352B (zh) * 2008-08-29 2011-12-21 苏州福英基因科技有限公司 一种早期子宫癌原位杂交检测试剂盒
ES2904911T3 (es) 2009-08-20 2022-04-06 Biosceptre Aust Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
EP3321285B1 (fr) 2009-12-24 2019-04-24 Biosceptre (Aust) Pty Ltd Anticorps dirigés contre les récepteurs p2x7 oligomères non fonctionnels
ES2656971T3 (es) 2010-09-10 2018-03-01 Biosceptre (Aust) Pty Ltd Tratamientos para el cáncer en animales de compañía con un anticuerpo anti P2X7
CN103702683B (zh) 2011-07-01 2017-07-04 生物权威(澳大利亚)有限责任公司 联合治疗
EP2990800A1 (fr) * 2014-08-29 2016-03-02 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Neprilysin comme marqueur pronostique pour l'insuffisance cardiaque
EP3347474B1 (fr) 2015-09-11 2020-11-04 Biosceptre (UK) Limited Récepteurs d'antigènes chimériques et leurs utilisations
EP3528789A4 (fr) * 2016-10-21 2020-06-24 Biosceptre UK Limited Particules cytotoxiques
CN110054691B (zh) * 2019-05-09 2021-09-07 潍坊医学院 一种抗人p2rx7单克隆抗体的杂交瘤细胞系

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133434A (en) * 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
CN100497385C (zh) * 2001-01-17 2009-06-10 因特里特控股有限公司 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途

Also Published As

Publication number Publication date
JP2005513416A (ja) 2005-05-12
JP4467973B2 (ja) 2010-05-26
CN1625565A (zh) 2005-06-08
NZ549019A (en) 2008-05-30
MY142283A (en) 2010-11-15
CA2459348C (fr) 2013-06-18
CN101445555A (zh) 2009-06-03
AU2002322192B2 (en) 2008-05-01
NZ565994A (en) 2010-02-26
WO2003020762A1 (fr) 2003-03-13
CA2459348A1 (fr) 2003-03-13
CN100497386C (zh) 2009-06-10
CN101445555B (zh) 2013-07-03
TWI329648B (en) 2010-09-01

Similar Documents

Publication Publication Date Title
ZA200402630B (en) Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions
IL209010A0 (en) Use of tnfalpha antibodies and another drug
ZA200305825B (en) Modified antibodies and methods of use
AU2003223285A8 (en) Human monoclonal antibodies to influenza m2 protein and methods of making and using same
IL206980A0 (en) Antibodies that bind human interleukin-18 and methods of making and using
AU2003295411A8 (en) Human monoclonal antibodies to heparanase
AP2000001983A0 (en) Antibodies to cd23 derivatives thereof and their therapeutic uses
EP1257287A4 (fr) Compositions et methodes permettant le depistage precoce du cancer de l'ovaire
EP1254267A4 (fr) Compositions et methodes permettant un diagnostic precoce du cancer ovarien
EP1386155A4 (fr) Utilisation therapeutique et diagnostique de profils de specificite d'anticorps
HUP0600688A3 (en) Methods of administering anti-tnf alpha antibodies
EP1581119A4 (fr) Compositions et procedes applicables a la therapie et au diagnostic pour la maladie intestinale inflammatoire
ZA200501308B (en) Agonism of the 5HT2a receptor for treatment of thermoregulatory dysfunction
AU2002340167A8 (en) Anti-hla-dr antibodies and the methods of using thereof
EP1492870A4 (fr) Anticorps se liant a l'integrine alpha-v-beta-6 et leurs methodes d'utilisation
AU2003256078A8 (en) Method of diagnosing colon and gastric cancers
EP1481078A4 (fr) Utilisation de la conjugaison peptide-medicament pour diminuer la variabilite entre sujets de niveaux de serum de medicament
AU2002351175A8 (en) Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof
IL151713A0 (en) Monoclonal antibodies to the human ldl receptor, their production and use
AU2003218208A8 (en) Methods for diagnosis and prognosis of cancer
AU2002224664A1 (en) Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions
AU2003276844A8 (en) Formulations of modified antibodies and methods of making the same
EP1391462A4 (fr) Peptide de liaison a des anticorps de la maladie de crohn et methode d'examen de ladite maladie
PL370739A1 (en) Pharmaceutical combinations of adenosine a-2a and beta-2-adrenergic receptor agonists
EP1409734A4 (fr) Diagnostic et traitement du cancer